Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging

Peter A. Pinto, Paul H. Chung, Ardeshir R. Rastinehad, Angelo A. Baccala, Jochen Kruecker, Compton J. Benjamin, Sheng Xu, Pingkun Yan, Samuel Kadoury, Celene Chua, Julia K. Locklin, Baris Turkbey, Joanna H. Shih, Stacey P. Gates, Carey Buckner, Gennady Bratslavsky, W. Marston Linehan, Neil D. Glossop, Peter L. Choyke, Bradford J. Wood

Research output: Contribution to journalArticlepeer-review

373 Scopus citations

Abstract

Purpose: A novel platform was developed that fuses pre-biopsy magnetic resonance imaging with real-time transrectal ultrasound imaging to identify and biopsy lesions suspicious for prostate cancer. The cancer detection rates for the first 101 patients are reported. Materials and Methods: This prospective, single institution study was approved by the institutional review board. Patients underwent 3.0 T multiparametric magnetic resonance imaging with endorectal coil, which included T2-weighted, spectroscopic, dynamic contrast enhanced and diffusion weighted magnetic resonance imaging sequences. Lesions suspicious for cancer were graded according to the number of sequences suspicious for cancer as low (2 or less), moderate (3) and high (4) suspicion. Patients underwent standard 12-core transrectal ultrasound biopsy and magnetic resonance imaging/ultrasound fusion guided biopsy with electromagnetic tracking of magnetic resonance imaging lesions. Chi-square and within cluster resampling analyses were used to correlate suspicion on magnetic resonance imaging and the incidence of cancer detected on biopsy. Results: Mean patient age was 63 years old. Median prostate specific antigen at biopsy was 5.8 ng/ml and 90.1% of patients had a negative digital rectal examination. Of patients with low, moderate and high suspicion on magnetic resonance imaging 27.9%, 66.7% and 89.5% were diagnosed with cancer, respectively (p <0.0001). Magnetic resonance imaging/ultrasound fusion guided biopsy detected more cancer per core than standard 12-core transrectal ultrasound biopsy for all levels of suspicion on magnetic resonance imaging. Conclusions: Prostate cancer localized on magnetic resonance imaging may be targeted using this novel magnetic resonance imaging/ultrasound fusion guided biopsy platform. Further research is needed to determine the role of this platform in cancer detection, active surveillance and focal therapy, and to determine which patients may benefit.

Original languageEnglish
Pages (from-to)1281-1285
Number of pages5
JournalJournal of Urology
Volume186
Issue number4
DOIs
StatePublished - Oct 2011
Externally publishedYes

Keywords

  • biopsy
  • early detection of cancer
  • magnetic resonance imaging
  • prostatic neoplasms
  • ultrasonography

Fingerprint

Dive into the research topics of 'Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging'. Together they form a unique fingerprint.

Cite this